For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Cost of goods sold | - | - | 288,527.5* | 287,005 |
| Net sales | - | - | 615,287.5* | 1,576,366 |
| Gross profit | - | - | 326,760* | 1,289,361 |
| Depreciation and amortization expense | - | - | 645,288.5* | 739,449 |
| Research and development expense | - | - | 1,179,320.5* | 588,355 |
| Intangible asset impairment | - | - | 741,690* | - |
| Api asset impairment | - | - | 1,104,215.5* | - |
| Selling, general and administrative | 990,737 | 1,800,778 | 7,404,916* | 2,301,305 |
| Total operating expenses | 990,737 | 1,800,778 | 11,075,430.5* | 3,629,109 |
| Loss from continuing operations | -990,737 | -1,800,778 | -10,748,670.5* | -2,339,748 |
| Interest expense, promissory note | - | - | 140,227.25* | - |
| Change in fair value of derivative liability | - | - | 815,181.25* | 202,000 |
| Change in fair value of warrant liability | -1,000 | 329,343 | - | - |
| Interest income | 67,014 | 88,849 | 78,957* | 75,817 |
| Amount of the cost of promissory notes accounted for as interest expense for debt | - | - | - | 158,730 |
| Total other income, net | 68,014 | -240,494 | 753,911* | 119,087 |
| Loss before income taxes | -922,723 | -2,041,272 | -9,994,759.5 | -2,220,661 |
| Loss from continuing operations, net of tax | -922,723 | -2,041,272 | - | - |
| Gain (loss) from discontinued operations | - | 500,816 | - | - |
| Gain from assignment of subsidiaries and vivus settlement | - | 6,973,302 | - | - |
| Net income (loss) | -922,723 | 5,432,846 | -9,994,759.5* | -2,220,661 |
| Preferred stock dividend and cash premiums | 231,210 | - | 405,382.5* | 1,051,695 |
| Preferred stock accretion | - | - | 4,424,566* | 1,974,359 |
| Net loss attributable to common stockholders | - | - | -14,824,708 | -5,246,715 |
| Net loss from continuing operations attributable to common stockholders | -1,153,933 | - | - | - |
| Basic EPS | -0.03 | -1.29 | -2.161 | -0.53 |
| Diluted EPS | -0.03 | -1.29 | -2.161 | -0.53 |
| Basic Average Shares | 42,284,502 | 25,922,503 | 6,860,214 | 9,829,793 |
| Diluted Average Shares | 42,284,502 | 25,922,503 | 6,860,214 | 9,829,793 |
Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc. (PTPI)